Insider Deck research · News

URGN stock news · UroGen Pharma Ltd.

Latest UroGen Pharma Ltd. (URGN) stock news, headlines, and research context on Insider Deck. Sector: Healthcare. Industry: Biotechnology. Market cap $2.3B.

News desk

UroGen Pharma Ltd. wire

Read the briefing on Insider Deck — headline, teaser, and desk context stay here. Publisher sites remain optional for the full longform.

8 on the wireUpdated within the hour

MarketBeat·Wed, Aug 5, 8:04 PM

Urogen Pharma Q2 Earnings Call Highlights

Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain traction. The company recorded a net loss of $14.4 million, or $0.28 per share, compared with a $49.

Insider Deck desk note

Last$46.43
Day+16.31%
SymbolURGN

Cross-check the tape against filings and ownership — the headline is the spark; the desk is the research.

Company KPIsShareholdersBuys vs Sells
Continue on MarketBeat

Frequently asked questions

What is the latest news on URGN?

The URGN news desk aggregates recent headlines with research context for UroGen Pharma Ltd. (Healthcare).

Where can I research URGN on Insider Deck?

UroGen Pharma Ltd. (URGN) research covers KPIs, earnings, fundamentals, institutional ownership, 13F flow, news, and DCF valuation.